Extra-corporeal photopheresis (ECP) showed a favorable safety profile in a prospective phase-Ib/II trial aimed at severe immune-related adverse events in cancer patients receiving immune checkpoint inhibitors. The study, published in Nature Communications, evaluated ECP specifically in the irAE setting, where steroid-refractory cases often create urgent treatment needs. In a separate study context, a rare case report described how extensive reconstruction using a customized 3D-printed titanium scaffold and vascularized fibular flap addressed a large femoral defect—relevant mainly to device-enabled regenerative and surgical innovation rather than drug pipelines. For biotech professionals, the ECP trial adds a practical immunotoxicity-management data point that can influence supportive-care pathways alongside tumor-directed therapies.